A Phase 3 interventional study of Donepezil in Alzheimer's Disease, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 45 Years to 91 Years. Per ClinicalTrials.gov, last updated 2021-11-17.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.
Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 2nd largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 10 in phase 3, and was the 20th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50+
Eisai Inc.
Ages 50–85
By country, each count listing its studies:
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 45 Years to 91 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 915 is above the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 79 across the 58 interventional studies. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
46 studies in Alzheimer Disease by Eisai Co., Ltd.: 7 open now, 12 under way, 2 of them phase 3. Of 33 finished, 11 (33%) have results posted.
Among the 46 studies in Alzheimer Disease by Eisai Co., Ltd., this one is the 5th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2007, is one of 8 in phase 3, and was the 10th registered.
Eisai Co., Ltd.’s Alzheimer Disease studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing donepezil in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 46 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of long-term administration of 23 milligram (mg) donepezil sustained release (SR) in participants with moderate to severe Alzheimer's disease. Participants who complete study E2020-G000-326 (NCT00478205) with no ongoing serious adverse events (SAEs) and no serious adverse drug reactions will be eligible to enter the open-label extension study.
Inclusion Criteria for Participants:
Inclusion Criteria for Caregivers. Written informed consent will be obtained from the designated caregiver for participation in study assessments. The caregiver must be sufficiently familiar with the participant (as determined by the investigator) to provide accurate data. Specifically, the caregiver must have sufficient contact with the participant to provide accurate reports of the participant's functioning, must be able to observe for possible adverse events, and must be able to accompany the participant to all visits. It is preferable that the caregiver be the same as in study E2020-G000-326 (NCT00478205). If no replacement caregiver is available who meets the caregiver inclusion/exclusion criteria, the participant must be discontinued from the study.
Exclusion Criteria for Participants:
Exclusion Criteria for Caregivers.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).
Drug: Donepezil
Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg immediate release (IR) in the preceding double-blind study E2020-G000-326 (NCT00478205).
Drug: Donepezil
Donepezil SR 23 mg once daily orally.
Also known as: Aricept
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product, a change in treatment, or discontinuation of study drug, recurrence of an intermittent medical condition not present pretreatment, an abnormal laboratory test result was considered an AE if the identified laboratory abnormality led to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not. All AEs in Study 328 (NCT00566501) excluding treatment-emergent signs or symptoms continuing from Study 326 (NCT00478205) were reported.
Time frame: From the enrollment of the study up to 30 days after last dose of the study drug (up to 2 years 3 months)
Percentage of Participants With at Least 1 Treatment-Emergent Abnormal Laboratory Values (TEAVs): Hematology
A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range post-dose, but within the normal range prior to drug administration, or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration. Abnormal values for hematology parameters were: White Blood cells count: less than or equal to \[\<=\] 2,800/per millimeter (mm) or greater than or equal to \[\>=\] 16,000/mm; Neutrophils: \<=15 percent (%); Hemoglobin: Male (\<=11.5 gram per deciliter \[g/dL\]), Female (\<=9.5 g/dL); Hematocrit: Male (\<=37%), Female (\<=32%); Eosinophils: \>=10%; Platelet Count: \<=75,000/mm or \>=700,000/mm. Percentage of participants with at least 1 abnormal TEAV for hematology was reported.
Time frame: From the first dose of study drug up to 2 years 3 months
Percentage of Participants With at Least 1 TEAVs for Selected Parameters: Clinical Chemistry
A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range postdose, but within the normal range prior to drug administration,or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration.Abnormal values for clinical chemistry parameters were:Sodium:Less than(\<)130 milliequivalents per litre (mEq/L) or greater than(\>)150 mEq/L;Potassium:\<3 mEq/L or \>5.5 mEq/L; Calcium: \<8.4 milligram per deciliter (mg/dL) or \>1.5 mg/dL;Albumin: 50% lower limit of normal (LLN); Alkaline Phosphatase:\>=3\*upper limit of normal (ULN);Aspartate aminotransferase (AST):\>=3\*ULN;Alanine aminotransferase(ALT):\>=3\*ULN;Total Bilirubin:\>=2.0 mg/dL;Chloride:\<90 mEq/L or \>115 mEq/L;Creatinine:\>=2.0 mg/dL;Creatine phosphokinase:\>=3\*ULN;Blood Urea Nitrogen (BUN):\>=30 mg/dL. Percentage of participants with at least 1 abnormal TEAV (selected parameters) for clinical chemistry was reported.
Time frame: From the first dose of study drug up to 2 years 3 months
Change From Baseline in Severe Impairment Battery (SIB) Total Score
The SIB evaluated the severity of cognitive dysfunction in participants with more advanced dementia. Test questions measured attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses were allowed, thus decreasing the need for language output. Forty questions were included with a total possible score range of 0-100. Lower scores indicated greater cognitive impairment.
Time frame: At Baseline, Month 3, Month 6, Month 9 and Month 12
Change From Baseline in Mini-Mental State Examination (MMSE) Total Score
MMSE is a 30-point scale that measured orientation to time and place, registration, immediate and delayed recall, attention, language, and drawing. Scores ranged from 0 (most impaired) to 30 (no impairment). Lower score indicated more impairment.
Time frame: At Baseline, Month 3, Month 6, Month 9 and Month 12
Change From Baseline in Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Severe Scale (ADCS-ADL) Total Score
ADCS-ADL is a comprehensive battery of ADL questions used to measure a participant's functional capabilities. The modified ADCS-ADL-severe scale is a 19-item scale that has been validated for the assessment of participants with moderate to severe dementia. It measured the most appropriate basic and instrumental abilities (such as walking, grooming, bathing, and eating) in this participant population. Response to each item was obtained by interview with the caregiver. Ratings reflected caregiver observations about the participant's actual functioning and provided an assessment of change in the functional state of the participant over time. The total score ranged from 0 to 54. Lower scores indicated greater functional impairment.
Time frame: At Baseline, Month 3, Month 6, Month 9 and Month 12
Change From Baseline in Quality of Life-Alzheimer's Disease (Qol-AD) Total Score
QoL-AD is a 13-item quality of life instrument developed to specifically assess QoL in participants who have dementia. Each item was scored on a 4-point scale (poor, fair, good, excellent) and a single score was calculated, ranging from 13 (low functioning) to 52 (normal function). Higher score indicated better QoL. The QoL-AD total scores for the participants and caregiver were the sum of the 13 items on each test.
Time frame: At Baseline, Month 6 and Month 12
Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Total Score
EQ-5D is a health profile questionnaire assessing quality of life along 5 domains. Caregivers rated 5 domains of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 to 0. HSI total score ranged from 1 (full health) and 0 (worst health/death).
Time frame: At Baseline, Month 6 and Month 12
Change From Baseline in Screen for Caregiver Objective Burden (SCB) Total Score
The SCB is a 25-item instrument that questions caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from "0" (no occurrence) to "4" (occurrence with severe distress). The objective burden was the sum of the total numbers of (1 2 3 4) in all items. Total score ranged from 0 (low distress) to 100 (high distress).
Time frame: At Baseline, Month 6 and Month 12
Change From Baseline in Screen for Caregiver Subjective Burden (SCB) Total Score
The SCB is a 25-item instrument that questioned caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from "0" (no occurrence) to "4" (occurrence with severe distress). The subjective burden was the sum of the (total number with score\*score). Total score ranged from 0 (no occurrence) to 100 (occurrence with severe distress).
Time frame: At Baseline, Month 6 and Month 12
Number of Participants With Treatment Outcome Scale (TOS) Score
TOS is a pilot instrument designed to evaluate the caregiver's assessment of the participant's status. The caregiver was asked how much he/she thinks the participant has been helped by participating in the study. This instrument comprised a 7-point Likert scale in which a rating of 1=Very much improved; 2=Moderately improved; 3=Minimally improved; 4=About the same; 5=Minimally worse; 6=Moderately worse; 7=Very much worse. The total scale ranged from 1 (marked improvement) to 7 (marked worsening).
Time frame: At Months 6 and 12
Goal Attainment Scaling (GAtS) Score Total Score
GAtS is a technique that is standardized with respect to the general approach, but individualized with respect to the outcome goals of each participant. GAtS was designed to provide insight into the changes that are considered as important by the caregiver and (if feasible) by the participants. At study initiation, the participants (if capable) and, separately, the caregiver were asked to specify up to 4 goals for the participants during study participation. For each goal, a description of the current state (or one supplied with the help of the clinician if necessary) was provided to anchor the baseline assessment at 0, and other possible outcomes were described. The outcome for each goal was quantified by a 4-point scale that provided for improvement (+1, +2), no change (0) or worsening (-1, -2). Total score ranged from -30 (worsened) to 130 (most improved). Baseline score was set to be 50 (when scores of all goals are '0' \[no change\]).
Time frame: At Months 6 and 12
Participants took part in the study at 179 centers in Asia, Europe, North America, Oceania, South Africa, and South America during 14 December 2007 to 01 April 2010. This study E2020-G000-328 (NCT00566501) was a 12-month, open-label extension of study E2020-G000-326 (NCT00478205). Participants who had received donepezil 10 milligram (mg) immediate release (IR) or donepezil 23 mg sustained release (SR) during Study E2020-G000-326 (NCT00478205) were eligible for enrollment into this study.
| Milestone | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Started | 570 | 332 |
| Completed | 423 | 210 |
| Not completed | 147 | 122 |
| Withdrew: Adverse event | 68 | 59 |
| Withdrew: Medication non-compliance | 5 | 0 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Request of investigator or sponsor | 6 | 7 |
| Withdrew: Withdrawal by subject | 33 | 30 |
| Withdrew: Lack of efficacy | 8 | 3 |
| Withdrew: Other | 25 | 21 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product, a change in treatment, or discontinuation of study drug, recurrence of an intermittent medical condition not present pretreatment, an abnormal laboratory test result was considered an AE if the identified laboratory abnormality led to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not. All AEs in Study 328 (NCT00566501) excluding treatment-emergent signs or symptoms continuing from Study 326 (NCT00478205) were reported.
| Participants | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 416 | 259 |
A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range post-dose, but within the normal range prior to drug administration, or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration. Abnormal values for hematology parameters were: White Blood cells count: less than or equal to \[\<=\] 2,800/per millimeter (mm) or greater than or equal to \[\>=\] 16,000/mm; Neutrophils: \<=15 percent (%); Hemoglobin: Male (\<=11.5 gram per deciliter \[g/dL\]), Female (\<=9.5 g/dL); Hematocrit: Male (\<=37%), Female (\<=32%); Eosinophils: \>=10%; Platelet Count: \<=75,000/mm or \>=700,000/mm. Percentage of participants with at least 1 abnormal TEAV for hematology was reported.
| percentage of participants | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Percentage of Participants With at Least 1 Treatment-Emergent Abnormal Laboratory Values (TEAVs): Hematology | 9.5 | 10.9 |
A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range postdose, but within the normal range prior to drug administration,or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration.Abnormal values for clinical chemistry parameters were:Sodium:Less than(\<)130 milliequivalents per litre (mEq/L) or greater than(\>)150 mEq/L;Potassium:\<3 mEq/L or \>5.5 mEq/L; Calcium: \<8.4 milligram per deciliter (mg/dL) or \>1.5 mg/dL;Albumin: 50% lower limit of normal (LLN); Alkaline Phosphatase:\>=3\*upper limit of normal (ULN);Aspartate aminotransferase (AST):\>=3\*ULN;Alanine aminotransferase(ALT):\>=3\*ULN;Total Bilirubin:\>=2.0 mg/dL;Chloride:\<90 mEq/L or \>115 mEq/L;Creatinine:\>=2.0 mg/dL;Creatine phosphokinase:\>=3\*ULN;Blood Urea Nitrogen (BUN):\>=30 mg/dL. Percentage of participants with at least 1 abnormal TEAV (selected parameters) for clinical chemistry was reported.
| percentage of participants | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Percentage of Participants With at Least 1 TEAVs for Selected Parameters: Clinical Chemistry | 14.3 | 13.1 |
The SIB evaluated the severity of cognitive dysfunction in participants with more advanced dementia. Test questions measured attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses were allowed, thus decreasing the need for language output. Forty questions were included with a total possible score range of 0-100. Lower scores indicated greater cognitive impairment.
| score on a scale | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| At Baseline | 78.4 ± 19.05 | 77.2 ± 19.49 |
| Change at Month 3 | -1.7 ± 7.11 | -0.9 ± 6.55 |
| Change at Month 6 | -4.0 ± 9.52 | -2.8 ± 8.68 |
| Change at Month 9 | -5.5 ± 11.19 | -5.2 ± 9.71 |
| Change at Month 12 | -7.5 ± 12.99 | -6.7 ± 10.75 |
MMSE is a 30-point scale that measured orientation to time and place, registration, immediate and delayed recall, attention, language, and drawing. Scores ranged from 0 (most impaired) to 30 (no impairment). Lower score indicated more impairment.
| score on a scale | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Baseline | 14.1 ± 5.81 | 13.8 ± 6.02 |
| Change at Month 3 | -0.6 ± 2.27 | -0.5 ± 2.20 |
| Change at Month 6 | -1.3 ± 2.70 | -1.2 ± 2.53 |
| Change at Month 9 | -1.7 ± 2.95 | -1.7 ± 2.77 |
| Change at Month 12 | -2.3 ± 3.08 | -2.1 ± 3.04 |
ADCS-ADL is a comprehensive battery of ADL questions used to measure a participant's functional capabilities. The modified ADCS-ADL-severe scale is a 19-item scale that has been validated for the assessment of participants with moderate to severe dementia. It measured the most appropriate basic and instrumental abilities (such as walking, grooming, bathing, and eating) in this participant population. Response to each item was obtained by interview with the caregiver. Ratings reflected caregiver observations about the participant's actual functioning and provided an assessment of change in the functional state of the participant over time. The total score ranged from 0 to 54. Lower scores indicated greater functional impairment.
| score on a scale | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Baseline | 34.3 ± 11.26 | 34.3 ± 11.26 |
| Change at Month 3 | -1.6 ± 5.30 | -1.8 ± 5.27 |
| Change at Month 6 | -3.2 ± 6.13 | -3.7 ± 6.53 |
| Change at Month 9 | -4.6 ± 6.91 | -4.8 ± 7.46 |
| Change at Month 12 | -5.6 ± 7.62 | -6.8 ± 8.96 |
QoL-AD is a 13-item quality of life instrument developed to specifically assess QoL in participants who have dementia. Each item was scored on a 4-point scale (poor, fair, good, excellent) and a single score was calculated, ranging from 13 (low functioning) to 52 (normal function). Higher score indicated better QoL. The QoL-AD total scores for the participants and caregiver were the sum of the 13 items on each test.
| score on a scale | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Caregiver; Baseline | 31.6 ± 6.37 | 30.8 ± 6.62 |
| Caregiver; Change at Month 6 | -1.4 ± 5.17 | -1.4 ± 5.08 |
| Caregiver; Change at Month 12 | -1.8 ± 5.60 | -1.8 ± 5.28 |
| Participant; Baseline | 35.2 ± 6.65 | 34.5 ± 6.90 |
| Participant; Change at Month 6 | -0.2 ± 5.10 | -0.1 ± 4.95 |
| Participant; Change at Month 12 | -0.2 ± 5.02 | -0.2 ± 4.76 |
EQ-5D is a health profile questionnaire assessing quality of life along 5 domains. Caregivers rated 5 domains of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 to 0. HSI total score ranged from 1 (full health) and 0 (worst health/death).
| score on a scale | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Baseline | 0.76 ± 0.17 | 0.77 ± 0.19 |
| Change at Month 6 | -0.04 ± 0.15 | -0.04 ± 0.18 |
| Change at Month 12 | -0.06 ± 0.18 | -0.06 ± 0.19 |
The SCB is a 25-item instrument that questions caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from "0" (no occurrence) to "4" (occurrence with severe distress). The objective burden was the sum of the total numbers of (1 2 3 4) in all items. Total score ranged from 0 (low distress) to 100 (high distress).
| score on a scale | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Baseline | 9.8 ± 4.36 | 9.8 ± 4.74 |
| Change at Month 6 | 0.5 ± 3.76 | 1.0 ± 3.64 |
| Change at Month 12 | 1.2 ± 3.94 | 1.5 ± 3.98 |
The SCB is a 25-item instrument that questioned caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from "0" (no occurrence) to "4" (occurrence with severe distress). The subjective burden was the sum of the (total number with score\*score). Total score ranged from 0 (no occurrence) to 100 (occurrence with severe distress).
| score on a scale | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Baseline | 18.4 ± 10.98 | 18.5 ± 12.14 |
| Change at Month 6 | 1.7 ± 10.03 | 3.0 ± 9.63 |
| Change at Month 12 | 3.2 ± 10.30 | 4.3 ± 10.64 |
TOS is a pilot instrument designed to evaluate the caregiver's assessment of the participant's status. The caregiver was asked how much he/she thinks the participant has been helped by participating in the study. This instrument comprised a 7-point Likert scale in which a rating of 1=Very much improved; 2=Moderately improved; 3=Minimally improved; 4=About the same; 5=Minimally worse; 6=Moderately worse; 7=Very much worse. The total scale ranged from 1 (marked improvement) to 7 (marked worsening).
| Participants | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| At Month 6 — 1=Very much improved | 10 | 7 |
| At Month 6 — 2=Moderately improved | 56 | 29 |
| At Month 6 — 3=Minimally improved | 66 | 40 |
| At Month 6 — 4=About the same | 149 | 79 |
| At Month 6 — 5=Minimally worse | 130 | 73 |
| At Month 6 — 6=Moderately worse | 96 | 57 |
| At Month 6 — 7=Very much worse | 23 | 17 |
| At Month 12 — 1=Very much improved | 12 | 5 |
| At Month 12 — 2=Moderately improved | 37 | 20 |
| At Month 12 — 3=Minimally improved | 67 | 23 |
| At Month 12 — 4=About the same | 91 | 52 |
| At Month 12 — 5=Minimally worse | 103 | 42 |
| At Month 12 — 6=Moderately worse | 89 | 54 |
| At Month 12 — 7=Very much worse | 41 | 26 |
GAtS is a technique that is standardized with respect to the general approach, but individualized with respect to the outcome goals of each participant. GAtS was designed to provide insight into the changes that are considered as important by the caregiver and (if feasible) by the participants. At study initiation, the participants (if capable) and, separately, the caregiver were asked to specify up to 4 goals for the participants during study participation. For each goal, a description of the current state (or one supplied with the help of the clinician if necessary) was provided to anchor the baseline assessment at 0, and other possible outcomes were described. The outcome for each goal was quantified by a 4-point scale that provided for improvement (+1, +2), no change (0) or worsening (-1, -2). Total score ranged from -30 (worsened) to 130 (most improved). Baseline score was set to be 50 (when scores of all goals are '0' \[no change\]).
| score on a scale | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Caregivers; At Month 6 | -2.6 ± 9.63 | -3.2 ± 9.97 |
| Caregivers At Month 12 | -5.1 ± 11.10 | -5.9 ± 10.61 |
| Participants; At Month 6 | 2.2 ± 7.34 | -0.8 ± 8.26 |
| Participants; At Month 12 | 2.4 ± 7.89 | -0.6 ± 9.57 |
Collected over From the first dose of study drug up to 2 years 3 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | 14/570 (2.5%) | 80/570 (14%) | 415/570 (72.8%) |
| Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) | 5/332 (1.5%) | 56/332 (16.9%) | 259/332 (78%) |
| Event | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| SyncopeNervous system disorders | 6/570 | 6/332 |
| Urinary tract infectionInfections and infestations | 8/570 | 3/332 |
| FallInjury, poisoning and procedural complications | 7/570 | 2/332 |
| Mental status changePsychiatric disorders | 0/570 | 4/332 |
| pneumoniaInfections and infestations | 6/570 | 1/332 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/570 | 3/332 |
| DehydrationMetabolism and nutrition disorders | 2/570 | 3/332 |
| Transient ischemic attackNervous system disorders | 1/570 | 3/332 |
| AggressionPsychiatric disorders | 1/570 | 3/332 |
| InsomniaPsychiatric disorders | 0/570 | 3/332 |
| Event | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) |
|---|---|---|
| Weight decreasedInvestigations | 58/570 | 43/332 |
| FallInjury, poisoning and procedural complications | 54/570 | 25/332 |
| AgitationPsychiatric disorders | 33/570 | 28/332 |
| AggressionPsychiatric disorders | 29/570 | 23/332 |
| Urinary tract infectionRenal and urinary disorders | 33/570 | 20/332 |
| NauseaGeneral disorders | 12/570 | 20/332 |
| DiarrhoeaGastrointestinal disorders | 20/570 | 19/332 |
| InsomniaGastrointestinal disorders | 18/570 | 15/332 |
| VomitingGastrointestinal disorders | 9/570 | 15/332 |
| DepressionPsychiatric disorders | 15/570 | 12/332 |
The safety population included all participants who received at least one dose of the study medication during the open-label treatment period and had at least one post-baseline safety assessment.
| Age, Continuous(years) | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) | Total |
|---|---|---|---|
| Mean | 74.1 ± 8.67 | 74.5 ± 8.44 | 74.3 ± 8.58 |
| Sex: Female, Male(Participants) | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) | Total |
|---|---|---|---|
| Female | 373 | 202 | 575 |
| Male | 197 | 130 | 327 |
| Race/Ethnicity, Customized(Participants) | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) | Total |
|---|---|---|---|
| Black | 16 | 7 | 23 |
| White | 429 | 245 | 674 |
| Hispanic | 42 | 18 | 60 |
| Asian/Pacific | 80 | 60 | 140 |
| Other | 3 | 2 | 5 |
Ran from Dec 2007 to primary completion in Apr 2010, 27 months.
Results were first posted in Jun 2012, 2 years 2 months after primary completion.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 27 months is below that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil